IP Library Granted Patent US 10,935,559
Granted Patent B2
US 10,935,559 · App. 15/149,868 · Granted Mar 2, 2021

Methodologies and reagents for detecting fibrinolysis and hyperfibrinolysis

Inventors: Michael P. Chapman (Denver, CO); Ernest E. Moore (Denver, CO); Katherine M. Norem (Chicago, IL)
Assignees: Haemonetics Corporation; The Regents of the University of Colorado, a body corporate
G01N33/86C12Q1/56G01N33/49
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,935,559
App. No.
15/149,868
Granted
Mar 2, 2021
Kind
B2
Abstract

In some embodiments, the invention provides a container adapted for detecting hyperfibrinolysis or fibrinolysis in a blood sample using viscoelastic analysis comprising an interior having a coating comprises an inhibitor of fibrinolysis.

Claims (12)

1. A container adapted for detecting hyperfibrinolysis or fibrinolysis in a blood sample using viscoelastic analysis comprising an interior having a coating comprising an inhibitor of fibrinolysis and an inhibitor of platelet function,

Wherein the coating is produced by applying a solution comprising both the inhibitor of fibrinolysis and the inhibitor of platelet function to the interior of the container and drying the solution such that it forms the coating on the interior of the container.

2. The container of claim 1 , wherein the inhibitor of fibrinolysis is tranexamic acid.

3. The container of claim 1 , wherein the inhibitor of fibrinolysis is selected from the group consisting of aminocaproic acid, ε-aminocaproic acid, and aprotinin.

4. The container of claim 1 , wherein the viscoelastic analysis is performed using a thromboelastography analyzer system or in a thromboelastometry analyzer system.

5. The container of claim 1 , wherein the inhibitor of fibrinolysis is formulated with sugar in the coating.

6. The container of claim 1 , wherein the inhibitor is formulated with sodium azide in the coating.

7. The container of claim 1 , wherein the inhibitor of platelet function is a glycoprotein IIb/IIIa receptor inhibitor.

8. The container of claim 7 , wherein the glycoprotein IIb/IIIa receptor inhibitor is selected from the group consisting of abciximab, eptifibatide, and tirofiban.

9. The container of claim 1 , wherein the inhibitor of platelet function is an adenosine diphosphate (ADP) receptor inhibitor, adenosine reuptake inhibitor, or a thromboxane inhibitor.

10. The container of claim 1 , wherein the inhibitor of platelet function is cytochalasin D.

11. The container of claim 1 , wherein the container is located on a cassette, wherein the cassette further comprises a second container.

Assignments (3)
CONFIRMATORY LICENSE Recorded Sep 21, 2018
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047585/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2016
From: NOREM, KATHERINE M.
To: HAEMONETICS CORPORATION
Reel/Frame 038587/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2016
From: CHAPMAN, MICHAEL P.; MOORE, ERNEST E.
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 038704/0516 →
Continuity (2)
Division 14270269 · May 5, 2014
Related Publication 20160252534A1 · Sep 1, 2016